Slide 1: Schedule 14A Proxy Statement Information
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a
Slide 2: Filing Party / Date Filed
(3) Filing Party: (4) Date Filed:
Slide 3: Explanatory Note
Explanatory Note The purpose of this Schedule 14A is to file with the Securities and Exchange Commission (the “SEC”) a presentation that was used by BIOLASE, Inc. (the “Company”) in a teleconference with a proxy advisory firm on April 8, 2015 and that may be used by the Company from time to time in
Slide 4: Driving Value from a Global Market Leadership Position
Driving Value from a Global Market Leadership Position April 2015
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT Statements contained in this presentation that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this presentation concerning BIOLASE's prospects, strategic initiatives or anticipate
Slide 6: Company Overview
COMPANY OVERVIEW BIOLASE is a global medical device company that develops, manufactures and markets leading laser technology currently focused on the dental market Proprietary laser-based products incorporate technology covered by over 300 issued or pending patents worldwide Markets and distributes
Slide 7: Federico Pignatelli: A History
FEDERICO PIGNATELLI: A HISTORY The Company’s financial performance deteriorated significantly in the last 14 quarters of Mr. Pignatelli’s service, including a net loss of $11.5 million in 2013 and an $11.3 million net loss for the first six months of 2014 (during which Mr. Pignatelli was Chairman an
Slide 8: Share Price Performance During Pignatelli Tenure as CEO
SHARE PRICE PERFORMANCE DURING PIGNATELLI TENURE AS CEO BIOLASE misses analysts’ EPS estimates for Q1 2013 (5/7/13) BIOLASE reports a larger-than-expected Q2 2013 quarterly loss and discloses it "no longer expects to generate cash from operations overall for the year ending December 31, 2013" (8/7/1
Slide 9: Turnaround Is Underway and Momentum Is Strong
TURNAROUND IS UNDERWAY AND MOMENTUM IS STRONG Revitalized management team: CEO – Jeffrey Nugent CFO – David Dreyer Senior Vice President for Worldwide Sales and Account Management Vice President of Quality and Regulatory Affairs Vice President and Chief Marketing Officer Strong progress: Raised equi
Slide 10: Vastly Improved Financial Position
VASTLY IMPROVED FINANCIAL POSITION BIOLASE strengthened its balance sheet with two equity financings in July and November 2014 Raised a combined $47 million of gross proceeds from both new and existing shareholders In 2014, BIOLASE paid off and terminated its credit facilities Cash and cash equivale
Slide 11: Board Nominees: Keeping the Right Leadership in Place
BOARD NOMINEES: KEEPING THE RIGHT LEADERSHIP IN PLACE PAUL CLARK Chairman On June 16, 2014, the Board elected Mr. Clark as Chairman of the Board. Mr. Clark has served as Chairman, CEO and President of ICOS Corporation, which researched and marketed Cialis and was acquired by Eli Lilly and Company in
Slide 12: Strong Shareholder Support
STRONG SHAREHOLDER SUPPORT “ The future is bright for BIOLASE. It has the products, industry relationships, leadership, customer insight and sales and marketing capabilities to penetrate further into an environment that, to date, has not fully embraced the potential of dental lasers. Looking at a co
Slide 13: Proposal to Ratify Fee-Shifting Bylaw Amendment
PROPOSAL TO RATIFY FEE-SHIFTING BYLAW AMENDMENT BIOLASE has been a party to two costly and distracting lawsuits involving Mr. Pignatelli’s attempts to maintain control of the Company. On June 26, 2014, the Board adopted bylaw amendments, including one that shifted litigation expenses to the unsucces
Slide 14: Annual Meeting Agenda
ANNUAL MEETING AGENDA April 27, 2015 – 11AM PST Company Headquarters – Irvine, CA Five proposals to be voted on at our 2015 annual meeting: The election of five directors to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified; The ratificatio
Slide 15: Conclusion
CONCLUSION We believe: BIOLASE is an industry leader with a strong future. BIOLASE is transitioning out of a tumultuous time under Mr. Pignatelli’s leadership toward improved performance and stability. The Company’s financial position, product innovation, customer engagement and leadership are all v
Slide 16: Contact
Contact: Mike Carroll corporate@biolase.com 888-424-6527